Mayinglong Pharmaceutical Group Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayinglong Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
SSY Group Ltd
sales of 2.02 billion Chinese Renmimbi [US$305.76 million]
of which 94%
was Intravenous Infusion Solution and Others),
Anhui Fengyuan Pharmaceutical
(2.03 billion Chinese Renmimbi [US$307.17 million]
of which 63%
was Medicine Retail Circulation), and
Hengkang Medical Group Co Ltd
(2.18 billion Chinese Renmimbi [US$328.57 million]
of which 57%
Mayinglong Pharmaceutical Group Co Ltd reported sales of 2.10 billion Chinese Renmimbi (US$317.61 million)
December of 2016.
increase of 17.9%
versus 2015, when the company's sales were 1.78 billion Chinese Renmimbi.
Sales at Mayinglong Pharmaceutical Group Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 49%).
Sales of the Hospital Diagnosis and Treatment saw an increase
21.7% in 2016, from
117.21 million Chinese Renmimbi to 142.66 million Chinese Renmimbi.